Edgewise Therapeutics, Inc.
EWTX
Rang în acțiuni
#3979
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing... Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Preț acțiune
$38.12
Ultima sincronizare: 2026-10-19
Capitalizare de piață
$4.10B
Schimbare (1 zi)
2.50%
Schimbare (1 an)
147.69%
Țară
US
Tranzacționează Edgewise Therapeutics, Inc. (EWTX)
Categorie
Healthcare
Raport P/B pentru Edgewise Therapeutics, Inc. (EWTX)
Raport P/B la data de October 2026 TTM: 8.90
Conform celor mai recente rapoarte financiare și prețului acțiunilor Edgewise Therapeutics, Inc., raportul P/B actual (TTM) este 8.90. La sfârșitul anului 2023, compania avea un P/B de 2.19.
Istoricul raportului P/B pentru Edgewise Therapeutics, Inc. din 2019 până în 2026
Raport P/B la sfârșitul fiecărui an
| An | Raport P/B | Schimbă |
|---|---|---|
| 2026 (TTM) | 8.90 | 65.65% |
| 2024 | 5.37 | 145.74% |
| 2023 | 2.19 | 58.22% |
| 2022 | 1.38 | -49.87% |
| 2021 | 2.76 | -106.24% |
| 2020 | -44.18 | -49.57% |
| 2019 | -87.61 | 0.00% |
Raport P/B pentru companii similare sau competitoare
| Companie | Raport P/B | Diferență raport P/B | Țara |
|---|---|---|---|
| 6.251 | -29.73% |
US
|
|
| 13.2547 | 49.00% |
US
|
|
| 4.208 | -52.70% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -30.50% |
NL
|
